Atlas Trials

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Clinical trial NCT04633902 · UNKNOWN

Trial details

NCT number
NCT04633902
Sponsor
California Pacific Medical Center Research Institute
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Melanoma
Start date
2021-03-03
Primary completion
2023-06-30
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.